Sequoia Financial Advisors LLC Acquires Shares of 3,908 Teleflex Incorporated $TFX

Key Points

• Sequoia Financial Advisors LLC acquired 3,908 shares of Teleflex Incorporated during Q2, valued at approximately $462,000, as part of a broader trend of institutional investment in the company.
• Teleflex reported earnings of $3.73 per share for the last quarter, surpassing analyst expectations, with projected FY 2025 guidance set at 13.900-14.300 EPS.
• The company recently announced a $0.34 quarterly dividend, resulting in an annualized dividend yield of 1.0% and a payout ratio of 32.00%.

Sequoia Financial Advisors LLC acquired a new stake in Teleflex Incorporated (NYSE:TFX - Free Report) during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund acquired 3,908 shares of the medical technology company's stock, valued at approximately $462,000.

Other institutional investors have also modified their holdings of the company. Teacher Retirement System of Texas purchased a new stake in shares of Teleflex during the 1st quarter worth approximately $1,242,000. Amalgamated Bank boosted its stake in shares of Teleflex by 56.9% during the 1st quarter. Amalgamated Bank now owns 14,046 shares of the medical technology company's stock worth $1,941,000 after acquiring an additional 5,095 shares in the last quarter. New York State Teachers Retirement System boosted its stake in shares of Teleflex by 13.9% during the 1st quarter. New York State Teachers Retirement System now owns 45,063 shares of the medical technology company's stock worth $6,227,000 after acquiring an additional 5,482 shares in the last quarter. NorthCrest Asset Manangement LLC purchased a new stake in shares of Teleflex during the 2nd quarter worth approximately $299,000. Finally, Brown Advisory Inc. boosted its stake in shares of Teleflex by 34.2% during the 1st quarter. Brown Advisory Inc. now owns 2,524 shares of the medical technology company's stock worth $349,000 after acquiring an additional 643 shares in the last quarter. Hedge funds and other institutional investors own 95.62% of the company's stock.

Insider Transactions at Teleflex

In other news, Director Stuart A. Randle purchased 1,000 shares of the stock in a transaction on Tuesday, August 5th. The stock was purchased at an average price of $115.86 per share, with a total value of $115,860.00. Following the completion of the transaction, the director owned 7,547 shares in the company, valued at approximately $874,395.42. The trade was a 15.27% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Jaewon Ryu purchased 1,500 shares of the stock in a transaction on Tuesday, August 5th. The shares were purchased at an average cost of $115.00 per share, with a total value of $172,500.00. Following the transaction, the director owned 3,727 shares of the company's stock, valued at $428,605. This trade represents a 67.36% increase in their position. The disclosure for this purchase can be found here. Insiders have acquired 5,500 shares of company stock valued at $633,590 in the last ninety days. Company insiders own 1.40% of the company's stock.

Teleflex Price Performance

TFX stock opened at $130.42 on Tuesday. Teleflex Incorporated has a 1 year low of $108.90 and a 1 year high of $239.82. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.44 and a current ratio of 2.41. The stock's 50 day moving average price is $125.38 and its 200 day moving average price is $123.51. The firm has a market cap of $5.76 billion, a P/E ratio of 30.69, a PEG ratio of 1.79 and a beta of 1.05.

Teleflex (NYSE:TFX - Get Free Report) last issued its quarterly earnings results on Thursday, July 31st. The medical technology company reported $3.73 earnings per share for the quarter, topping analysts' consensus estimates of $3.36 by $0.37. The company had revenue of $780.90 million for the quarter, compared to analyst estimates of $771.53 million. Teleflex had a return on equity of 15.08% and a net margin of 6.31%.The business's revenue for the quarter was up 4.2% compared to the same quarter last year. During the same quarter in the prior year, the company posted $3.42 EPS. Teleflex has set its FY 2025 guidance at 13.900-14.300 EPS. On average, sell-side analysts expect that Teleflex Incorporated will post 13.98 earnings per share for the current fiscal year.

Teleflex Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Monday, September 15th. Investors of record on Friday, August 15th were given a $0.34 dividend. This represents a $1.36 annualized dividend and a dividend yield of 1.0%. The ex-dividend date of this dividend was Friday, August 15th. Teleflex's dividend payout ratio (DPR) is 32.00%.

Analysts Set New Price Targets

TFX has been the topic of several research analyst reports. Wells Fargo & Company decreased their price target on Teleflex from $137.00 to $131.00 and set an "equal weight" rating on the stock in a research note on Friday, August 1st. Mizuho boosted their price target on Teleflex from $130.00 to $135.00 and gave the stock a "neutral" rating in a research note on Friday, August 1st. Zacks Research lowered Teleflex from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, September 30th. Royal Bank Of Canada upped their target price on Teleflex from $130.00 to $135.00 and gave the company a "sector perform" rating in a research note on Friday, August 1st. Finally, Wall Street Zen lowered Teleflex from a "strong-buy" rating to a "buy" rating in a research note on Monday, September 15th. One equities research analyst has rated the stock with a Buy rating, nine have issued a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of "Reduce" and a consensus price target of $141.57.

Teleflex Company Profile

Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. The company provides vascular access products that comprise Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous access systems for the administration of intravenous therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.